Search

Displaying results 2361 - 2370 of 10000 in total
  1. Drug

    Eladocagene exuparvovec

    go.drugbank.com/drugs/DB16780
    ApprovedInvestigational

    [L43642] Eladocagene exuparvovec received EMA approval in July 2022. … [A253687] It was subsequently approved by the FDA in November 2024.[L51898,L51893]

  2. Drug

    Brincidofovir

    go.drugbank.com/drugs/DB12151
    ApprovedInvestigational

    Brincidofovir is an oral antiviral drug used in the treatment of human smallpox infections. … [L34470] As smallpox has been eradicated, the efficacy of Tembexa was assessed in animals infected with viruses closely related to variola.

  3. Drug

    Tetracaine

    go.drugbank.com/drugs/DB09085
    ApprovedInvestigationalVet approved

    Tetracaine is an ester local anaesthetic currently available in combination with lidocaine as a cream and patch.

  4. Drug

    Gadolinium

    go.drugbank.com/drugs/DB12091
    ApprovedInvestigationalWithdrawn

    Gadolinium is under investigation in Hypertension, ACUTE KIDNEY INJURY, and Chronic Kidney Disease.

    Categories: Compounds used in a research, industrial, or household setting
  5. Drug

    Butalbital

    go.drugbank.com/drugs/DB00241
    ApprovedIllicit

    Butalbital, or 5-allyl-5-isobutylbarbituric acid, is a derivative of barbituric acid which the hydrogens at position 5 are substituted by an allyl group and an isobutyl group. … [L10370] Butalbital‐containing analgesics can also produce a drug‐induced headache in addition to tolerance and dependence.

    Synonyms: 5-allyl-5-(2'-methyl-n-propyl) barbituric acid
  6. Drug

    Concizumab

    go.drugbank.com/drugs/DB12820
    ApprovedInvestigational

    [L52043] Concizumab-mtci (Alhemo) was approved by the FDA in December 2024 for use in patients with hemophilia A or B with inhibitors. … [A264883,A264878] In patients with hemophilia A or B - characterized by deficiencies in clotting factors VIII or IX, respectively - the traditional treatment involves replacement of the missing clotting

  7. Drug

    Cidofovir

    go.drugbank.com/drugs/DB00369
    ApprovedInvestigational

    Cidofovir is an injectable antiviral medication employed in the treatment of cytomegalovirus (CMV) retinitis in patients diagnosed with AIDS. … [FDA label] It was manufactured by _Gilead_ and initially approved by the FDA in 1996, but has since been discontinued.[L6223]

  8. Drug

    Human cytomegalovirus immune globulin

    go.drugbank.com/drugs/DB13886
    ApprovedInvestigational

    The seroprevalence of antibodies in adults ranges from 40-100 % with an inverse correlation to socioeconomic status. … During the span of an individual's life, the virus may reactivate, resulting in repeated shedding and spread of the virus.

  9. Drug

    Vorinostat

    go.drugbank.com/drugs/DB02546
    ApprovedInvestigational

    It is the first in a new class of agents known as histone deacetylase inhibitors. … A recent study suggested that vorinostat also possesses some activity against recurrent glioblastoma multiforme, resulting in a median overall survival of 5.7 months (compared to 4 - 4.4 months in earlier

  10. Drug

    Netarsudil

    go.drugbank.com/drugs/DB13931
    ApprovedInvestigational

    humour outflow to act as an inhibitor to the rho kinase and norepinephrine transporters found there as opposed to affecting protaglandin F2-alpha analog like mechanisms in the unconventional uveoscleral … production of aqueous As of December 18, 2017 the FDA approved Aerie Pharmaceutical's Rhopressa (netarsudil ophthalmic solution) 0.02% for the indication of reducing elevated intraocular pressure in